Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study being ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

Using tirzepatide and menopause hormone therapy at the ... "This study underscores the urgent need for further research to ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their prescribed obesity medication, according to findings published in Obesity.

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and ...